Purchase Order HT941024P0214
Award Date
10/1/24
Potential Completion Date
9/30/27
Potential Value
$232K
Federal Agency
Defense Health Agency
Awardee
Cerus Corporation
Ultimate Awardee
Not listed
NAICS Category
325413 - In-Vitro Diagnostic Substance Manufacturing
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Not Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Concord, CA 94520, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This firm fixed-price purchase order contract was awarded by the Defense Health Agency (DHA) to Cerus Corporation, a biomedical products company specializing in blood safety technologies and pathogen reduction systems. The $369,384 contract is for the provision of Cerus' proprietary INTERCEPT Blood System, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components, including platelets and plasma. This pathogen reduction technology plays a critical role in reducing...
The Defense Health Agency awarded Cerus Corporation, a biomedical products company, a firm-fixed-price purchase order contract worth $190,080.00 for the supply of INTERCEPT Platelet Processing Sets and INTERCEPT Platelet Processing Sets with Dual Storage Containers. The contract is a sole-source award due to the proprietary nature of Cerus Corporation's INTERCEPT Blood System technology, which uses riboflavin and ultraviolet light to inactivate pathogens in blood components. This pathogen...
This is a $199,584.00 firm fixed-price purchase order awarded by the Defense Health Agency to Cerus Corporation, a biomedical products company that specializes in blood safety technologies. The contract is for the supply of INTERCEPT platelet processing sets, which use the company's proprietary INTERCEPT Blood System to inactivate pathogens in blood components. This system plays a crucial role in reducing the risk of transfusion-transmitted infections in blood products used by military and...
This federal contract award was issued by the Bureau of Medicine and Surgery, a defense agency, to Cerus Corporation, a biomedical products company specializing in blood safety technologies. The $138,800 firm-fixed-price contract is for the supply of INTERCEPT Illuminator 60 Hz equipment and INTERCEPT Platelet Processing Sets with Dual Storage, as well as related services, to support the agency's blood product safety requirements. Cerus Corporation's proprietary INTERCEPT Blood System uses...
The Defense Health Agency (DOD) awarded a $367,504.80 firm fixed price purchase order to Cerus Corporation to provide INTERCEPT Platelet Processing and Service Maintenance for the Walter Reed National Military Center in Bethesda, Maryland from January 13, 2022 through January 31, 2027. Cerus Corporation will supply its INTERCEPT Blood System for platelets, which utilizes ultraviolet light and riboflavin to inactivate pathogens in platelet components during the collection and storage process,...
The Defense Health Agency awarded a Firm Fixed Price, $186,048.00 purchase order contract to Cerus Corporation, a biomedical products manufacturer, for the drop shipment of medical supplies. The contract is sole source and not set aside. The supplies include the INTERCEPT Blood System technology, which uses riboflavin and UV light to inactivate pathogens in blood platelets and plasma. Cerus has received over 20 federal contract awards since 2002 from agencies such as the Department of Defense,...
This federal contract award with ID 75A50124C00046 was made by the Office of the Assistant Secretary for Preparedness and Response (ASPR), a civilian agency, to Cerus Corporation, a for-profit manufacturer. The $188,446,002.15 cost-sharing contract is for the license of Cerus' proprietary Pathogen Reduction Technology (PRT) for red blood cell (RBC) components, with the goal of reducing the risk of transfusion-transmitted infections by recognized, emerging, epidemic, and endemic pathogens. This...
The Defense Health Agency awarded Cerus Corporation a firm fixed price purchase order valued at $295,380 for INTERCEPT platelet processing sets. The award stems from a sole source pre-solicitation notice by the Naval Medical Logistics Command seeking the same platelet pathogen reduction products and annual technical services to support an existing Cerus system at the United States Naval Hospital in Guam. Cerus will provide INTERCEPT platelet small volume processing sets, INTERCEPT platelet...
This is a firm-fixed price purchase order awarded by the Veterans Integrated Service Network 12 (VISN 12), a civilian agency within the Department of Veterans Affairs, to Cerus Corporation, a biomedical company specializing in blood safety technologies and pathogen reduction systems. The $82,389 contract is for the supply of INTERCEPT Illuminator 60 Hz systems and associated maintenance services. The illuminators are essential components of Cerus Corporation's proprietary INTERCEPT Blood System,...
The Department of the Navy Bureau of Medicine and Surgery awarded a firm fixed price purchase order to Cerus Corporation, a biomedical products manufacturer, for the procurement of 2 INTERCEPT ILLUMINATOR 60HZ - INT100-60 units. The $110,000.00 contract has a completion date of September 8, 2017. Cerus Corporation has received over 20 prime federal contracts from agencies such as the Defense Health Agency, Department of Defense, and Department of Veterans Affairs to provide goods and services...